HC Wainwright & Co. Maintains Buy on RVL Pharmaceuticals, Lowers Price Target to $3
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on RVL Pharmaceuticals (NASDAQ:RVLP) but lowers the price target from $4 to $3.
August 21, 2023 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on RVL Pharmaceuticals, indicating continued confidence in the company's prospects.
The lowered price target could potentially indicate a perceived decrease in RVL Pharmaceuticals' future earnings potential. However, the maintained 'Buy' rating suggests that the analyst still sees value in the company's stock, which could balance out any negative impact from the lowered price target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100